yrosine kinases are key regulators of intracellular signaling. 1,2 Overexpressed or mutated tyrosine kinases occur in many types of cancer and contribute to the development and progression of tumors. [3] [4] [5] The dependence of tumor cells on persistently activated tyrosine kinases may render tumors susceptible to inhibitors of these kinases. [3] [4] [5] [6] [7] The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is a target for such inhibitors because it is amplified, mutated, or both in a number of neoplasms. 8 A small subgroup of patients with lung cancer have a response to EGFR inhibitors, [9] [10] [11] and mutations in the EGFR kinase domain have been associated with responsiveness. [12] [13] [14] It is not known, however, whether such mutations affect the responsiveness of other types of cancer to EGFR kinase inhibitors.
Among patients with glioblastoma, the most common primary malignant brain tumor of adults, a small subgroup seems to benefit from the EGFR kinase inhibitors erlotinib and gefitinib. 15, 16 However, the infrequency of mutations in the EGFR kinase domain in glioblastomas 17, 18 suggests that such EGFR mutations cannot account for responsiveness to EGFR kinase inhibitors. 19 The EGFR gene is commonly amplified in glioblastoma, 20 but this abnormality also does not correlate with responsiveness to EGFR kinase inhibitors. 16 Glioblastomas often express EGFRvIII, a constitutively active genomic deletion variant of EGFR. [21] [22] [23] [24] [25] This variant of EGFR strongly and persistently activates the phosphatidylinositol 3' kinase (PI3K) signaling pathway, which provides critical information for cell survival, proliferation, and motility. [26] [27] [28] [29] [30] Persistent PI3K signaling -as would be instigated by EGFRvIII -is believed to cause "pathway addiction" 31 ; addicted tumor cells die if the pathway is disrupted by tyrosine kinase inhibitors. By promoting chronic dependence on PI3K signaling, EGFRvIII may sensitize glioblastoma cells to EGFR kinase inhibitors.
The PTEN (phosphatase and tensin homologue deleted in chromosome 10) tumor-suppressor protein, an inhibitor of the PI3K signaling pathway, is commonly lost in glioblastoma. 20, 27, 32 This loss may promote cellular resistance to EGFR kinaseinhibitor therapy by dissociating EGFR inhibition from downstream PI3K pathway inhibition (Fig.  1) . 33 We hypothesized that EGFRvIII would sensitize tumors to EGFR kinase inhibitors, whereas PTEN loss would impair the response to such inhibitors. 33 To test this hypothesis, we analyzed EGFRvIII and PTEN at the gene and protein levels in glioblastomas from patients before treatment with EGFR kinase inhibitors. We also searched for mutations in EGFR and in its heterodimerization partner Her2/neu , which has been reported to be mutated in glioblastoma and could also affect the response to EGFR kinase inhibitors. 34 We found a strong association between the coexpression of EGFRvIII and PTEN in glioblastoma cells and responsiveness to EGFR kinase inhibitors.
test set
Since 2001, 49 patients with recurrent glioblastoma have been treated at the University of California, Los Angeles (UCLA) -37 with gefitinib and 12 with erlotinib -as part of three multi-institutional clinical trials approved by the institutional review board. The clinical studies were performed through the Cancer Therapy Evaluation Program of the National Institutes of Health or Genentech. The correlative study described here was conducted independently and without industry support. Diagnoses were established by two neuropathologists and confirmed by a third pathologist who was unaware of the results of molecular analyses. Tumor specimens were obtained according to a protocol approved by the institutional review board of UCLA. All patients had measurable disease on magnetic resonance imaging (MRI) and had stopped receiving any previous cancer treatment at least four weeks before the start of monotherapy with an EGFR inhibitor.
MRI and clinical assessment were performed at baseline, every two months thereafter, and at the time of progression by a neuroradiologist and a neuro-oncologist who were unaware of the results of the molecular analyses. A response was defined as a decrease of at least 25 percent in the bidirectional area of the contrast-enhancing tumor on MRI in the absence of an increased dose of corticosteroids. Progression was defined as an increase of at least 25 percent in the bidirectional tumor area. Thirty-seven patients, 26 with clear-cut evidence of a response or progression, had sufficient tissue for molecular analysis (Tables 1 and 2 ). Ten patients fell between these extremes of response to treatment, with tumor growth or shrinkage of 25 percent or less (details are provided in Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). One patient was excluded because a response occurred coincidently with an increase in the dose of decadron. The statistical methods used are described in the Supplementary Appendix.
validation set
We obtained paraffin-embedded slides from biopsy specimens of malignant glioma from 33 patients who received erlotinib at the University of California, San Francisco (UCSF). Frozen tissue was not available from these patients. Immunohistochemical evaluation of EGFRvIII and PTEN was scored semiquantitatively by two UCLA pathologists who were unaware of the clinical results. 
Fluorescence in Situ Hybridization
Dual-probe fluorescence in situ hybridization (FISH) was performed on paraffin-embedded sections with locus-specific probes for EGFR and the centromere of chromosome 7 ( CEP7 ) (Vysis). Standard FISH protocols for pretreatment, hybridization, and analyses were followed according to the manufacturer's instructions. 20 The EGFR becomes activated on binding to epidermal growth factor and recruits PI3K to the cell membrane. PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to the second-messenger molecule PIP 3 (blue arrows). This second messenger then activates downstream effector molecules, such as Akt and the mammalian target of rapamycin (mTOR), which help induce cellular proliferation and block apoptosis. PTEN terminates the PIP 3 signal (red arrows). The mutant receptor EGFRvIII is persistently activated in the absence of ligand, owing to an in-frame deletion within the extracellular ligand-binding domain. The new england journal of medicine sponse) and subjected to real-time PCR with the use of the iCycler thermocycler (Bio-Rad Laboratories). All measurements were made in triplicate and confirmed by independent experiments. The Supplementary Appendix lists the primer sequences used and provides complete details.
Immunohistochemistry and Immunoblotting
Paraffin-embedded tissue sections underwent immunohistochemical analysis in which the results were scored independently by two pathologists who were unaware of the findings of the molecular analyses. Scores of 0 and 1 were considered to indicate PTEN loss. 27 If staining for PTEN was heterogeneous, tumors with diminished or absent staining in at least 25 percent of the section were considered PTEN-deficient. Tumors demonstrating focal, moderate-to-strong immunostaining for EGFRvIII were considered positive. 27 Quantitative image analysis to confirm the pathologists' scor-* KD denotes kinase domain, FISH fluorescence in situ hybridization, IHC immunohistochemical analysis, ND RNA degraded, NA no frozen tissue available, NT no tissue slide available, plus sign positive results, and minus sign negative results. † The results were confirmed by a ratio of EGFR exon 9 DNA to exon 4 DNA of 4.79. † An odds ratio could not be calculated because none of the UCLA patients with PTEN-deficient tumors had a response, but if 0.5 is added to each cell count, the odds ratio is 31 (95 percent confidence interval, 1.5 to 633.0). ‡ The test had a sensitivity of 86 percent and a specificity of 89 percent in the UCLA group and a positive predictive value of 75 percent. § A subgroup of patients in the UCSF study received concurrent temozolomide. All UCLA patients received monotherapy with an EGFR kinase inhibitor. ¶ The test had a sensitivity of 63 percent, a specificity of 96 percent, and a positive predictive value of 89 percent. (Table 3) .
mutations in the egfr kinase domain
We sequenced the kinase domain of EGFR in the glioblastomas from the 26 patients. The quality of results
Figure 2 (facing page). EGFRvIII and PTEN in Glioblastomas.
Panel the DNA was sufficient to allow us to sequence the entire kinase domain of EGFR (exons 18 through 24) in six of seven patients with a response and exon 21 alone in Patient 6. No mutations were detected in the seven patients with a response or in eight of the patients with no response for whom DNA was available for sequencing (Table 2) . Thus, mutations in the EGFR kinase domain are unlikely to determine the sensitivity of glioblastomas to EGFR kinase inhibitors. We also sequenced the kinase domain of Her2/neu and found no mutations. 
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Anti-EGFRvIII of nucleic acid-based assays (RT-PCR and the ratio of EGFR exon 9 DNA to exon 4 DNA) and immunoblotting in the 15 available samples of frozen tumor ( Fig. 2A and 2B and Table 2 ). We found complete agreement between the nucleic acid-based assays and immunohistochemical analysis ( k =1.0, P< 0.001) and between immunoblotting and immunohistochemical analysis ( k =1.0, P<0.001) (Fig. 3 of the Supplementary Appendix). These results are consistent with recent findings by another group 21 and provide support for the use of immunohistochemical analysis to determine the EGFRvIII status in the remaining 11 patients for whom no frozen tissue was available.
EGFRvIII was detected in 12 of 26 malignant gliomas (46 percent) ( Table 2 ), similar to the previously reported frequency in glioblastomas. 21, 27 It was found only in tumors with EGFR amplification or a gain of chromosome 7. Of 12 patients whose tumors expressed EGFRvIII, 6 had a response to EGFR kinase inhibitors, whereas 1 of 14 patients whose tumors did not express EGFRvIII had a response to EGFR kinase inhibitors (P=0.03). These data suggested that the expression of EGFRvIII sensitizes gliomas to EGFR kinase inhibitors. However, the lack of response in 50 percent of patients with EGFRvIII-expressing tumors indicates that other factors influence the outcome of treatment.
Since PTEN may be required for a response to the EGFR family of kinase inhibitors, 33 we studied this protein in glioblastomas using immunohistochemical analysis and immunoblotting (Fig. 2C) . The results of both assays were concordant ( k =0.8, P=0.005). None of 13 patients whose tumors lacked PTEN had a response to EGFR inhibitors, whereas 7 of 13 patients with PTEN-positive tumors had a response (P=0.005) ( Table 3) . To rule out the possibility that the immunohistochemical assay detected a mutant protein, we sequenced PTEN; no mutations were detected in the responsive tumors. The greatest likelihood of a clinical response to EGFR kinase inhibitors was associated with coexpression of EGFRvIII and PTEN (odds ratio, 51; 95 percent confidence interval, 4 to 669; P<0.001) ( Table 3) .
Ten patients who had neither tumor regression nor substantial tumor growth while receiving an EGFR kinase inhibitor (Table 1 of the Supplementary Appendix) were excluded from the original analysis because they did not fit the extremes of a clear response or treatment failure. None of these patients, who had a median time to progression of 3.7 months, had tumors that coexpressed EGFRvIII and PTEN (Table 1 of the Supplementary Appendix).
validation set
We analyzed the expression of EGFRvIII and PTEN in 33 gliomas from patients who were treated with erlotinib at a different institution, UCSF ( Table 2 of the Supplementary Appendix). Of these 33 patients, 8 had a clinical response. A clinical response in this group was also significantly associated with the coexpression of EGFRvIII and PTEN (odds ratio, 40; 95 percent confidence interval, 3 to 468; P=0.001) ( Table 3 ). We induced the expression of relevant combinations of PTEN, EGFR, and EGFRvIII in U87MG glioblastoma cells. U87MG cells are deficient in PTEN, [35] [36] [37] [38] express low levels of wild-type EGFR, and lack EGFRvIII. 39, 40 Coexpression of EGFRvIII and PTEN in these glioblastoma cells rendered them highly susceptible to arrest of growth by erlotinib, as compared with control cells and U87MG cells that were transfected with other components of the PTEN-EGFR system (Fig. 3A) . In these experiments, erlotinib caused the arrest of growth but not apoptosis in U87MG cells. Because U87MG cells do not depend on EGFR signaling for survival, we examined the effect of a lack of PTEN in three cell lines that undergo apoptosis in the presence of EGFR kinase inhibitors: SF295 human glioblastoma cells, mouse embryonic fibroblasts from mice in which the PTEN gene has been conditionally inactivated, 45 and A431 cells with stable PTEN RNAi (Fig. 3B ). These experiments were performed with two EGFR kinase inhibitors, erlotinib and PKI-166. 41 In all three systems, the lack of PTEN abrogated or markedly reduced the extent of apoptosis induced by the two inhibitors of EGFR kinase (Fig. 3B) . We examined the contribution of Akt to the resistance to EGFR kinase inhibitors conferred by the loss of PTEN, because many of the effects that follow the loss of PTEN occur through the activation of the downstream kinase Akt. 46 Erlotinib-induced inhibition of the phosphorylation of Akt correlated with growth inhibition in U87MG cells (Fig. 4 of the Supplementary Appendix), but not in all cell lines. For example, in A431 cells expressing PTEN shRNA, phosphorylation of Akt was blocked by EGFR kinase inhibitors (Fig. 5 of the Supplementary Appendix, lanes 3 and 4), but the cells remained viable (Fig. 3B) . Furthermore, overexpression of a membrane-targeted and persistently activated allele of Akt 47 (Fig. 5 of the Supplementary Appendix, lanes 5 and 6) did not prevent A431 cells from undergoing apoptosis mediated by EGFR kinase inhibitors (Fig. 3C) . These findings suggest that Aktindependent branches of the PTEN pathway may contribute to the effects of PTEN on the sensitivity of tumors to EGFR kinase inhibitors. We also noted that the levels of EGFR and EGFRvIII phosphorylation were consistently higher in PTEN-deficient cells than in their PTEN-expressing counterparts, suggesting that PTEN affects the receptor protein itself (Fig. 6 of the Supplementary Appendix). Taken together, these results suggest the existence of multiple mechanisms by which the loss of PTEN promotes resistance to EGFR kinase inhibitors in glioblastoma cells.
In this study of glioblastomas from patients who were treated with gefitinib or erlotinib, we found that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression by the tumor of EGFRvIII and PTEN. EGFRs with mutations in the tyrosine kinase domain selectively activate antiapoptotic signals through the PI3K-Akt signaling pathway (Fig. 1) . 26 Akt, a kinase involved in cellular proliferation and apoptosis, is activated by signals generated by PI3K. Inhibition of this antiapoptotic signal by gefitinib appears to be critical to the efficacy of the drug. 26 Like the EGFR kinase domain mutants in lung cancer, EGFRvIII, a constitutively active mutant variant of EGFR, preferentially activates PI3K-Akt signaling and can sensitize glioblastoma cells to EGFR kinase inhibitors. [26] [27] [28] [29] [30] Loss of PTEN, a tumor-suppressor protein that inhibits the PI3K signaling pathway, may promote resistance to EGFR kinase inhibitors. 33 We found that the lack of PTEN in gliomas is associated with resistance to EGFR kinase inhibitors. Moreover, in four isogenic cell lines, loss of PTEN markedly diminished responsiveness to EGFR kinase inhibitors. Our evidence suggests that both Akt-dependent and Akt-independent mechanisms underlie the resistance caused by a loss of PTEN.
These results suggest that screening of tumors for PTEN protein may be warranted in patients with cancers with EGFR kinase mutations that do not respond to gefitinib, erlotinib, or related EGFR kinase inhibitors. Our data also suggest that downstream inhibition of the PI3K pathway, perhaps at the level of the mammalian target of rapamycin (a kinase related to PI3K) (Fig. 1) , could be combined with EGFR kinase inhibitors in patients with PTENdeficient tumors to promote responsiveness. 48 These studies also raise the possibility that more complete inhibition of EGFR phosphorylation may overcome the resistance to kinase inhibitors caused by a deficiency of PTEN.
In summary, we have implicated EGFRvIII and PTEN as molecular determinants of the sensitivity of glioblastomas to EGFR kinase inhibitors. Pro- spective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in independent data sets is warranted.
